AstraZeneca had a disappointing trial readout with its AKT inhibitor Truqap in breast cancer in June, so unsurprisingly it is trumpeting a first-in-class win for the drug in prostate cancer.

AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.

We've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer that ...

AstraZeneca’s Truqap (capivasertib) has been approved for use by the National Health Service (NHS) in England and Wales, providing a new targeted therapy option that significantly increases ...

The drug, also known as Truqap and made by British pharmaceutical giant AstraZeneca, helps slow or stop the progression of the cancer, meaning it could help some patients live longer. "People with ...

The drug, capivasertib (also known as Truqap), offers new hope for up to 3,000 women annually with hormone receptor (HR)-positive, HER2-negative breast cancer harbouring specific genetic mutations ...